Development of beta-lactamase inhibitors of clinical interest.

• Grant number: 19/27813-8
• Support type: Regular Research Grants
• Duration: September 01, 2020 - August 31, 2022
• Field of knowledge: Biological Sciences - Biochemistry - Enzymology
• Principal Investigator: Marcelo Ferreira Marcondes Machado
• Grantee: Marcelo Ferreira Marcondes Machado
• Home Institution: Instituto Nacional de Farmacologia (INFAR). Universidade Federal de São Paulo (UNIFESP). São Paulo , SP, Brazil
• Assoc. researchers: Ana Cristina Gales ; Camilla Abbehausen ; Vitor Marcelo Silveira Bueno Brandão de Oliveira

Abstract

Due to the emergence of bacteria resistant to current antibiotics, the development of new antibiotics remains one of the biggest challenges of modern medicine. In Gram negative bacilli, the production of ²-lactamases is the most important contributing factor for the acquisition of resistance to ²-lactam antimicrobials. Inhibitors developed for these ²-lactamases act in conjunction with ²-lactam antibiotics, however, a decrease in the efficiency of these combinatorial therapies has been observed, mainly through the action of variants and new ²-lactamases capable of degrading these compounds. The main objective of this project is the development of ²-lactamase inhibitors, identified and isolated from pathogenic strains presenting differentiated resistance phenotype, by using two main approaches: 1) From a cyclic peptide library previously prepared by a technique Based on split-integer properties, SICLOPPS (Split Intein-mediated Circular Ligation Of Peptides and ProteinS) with random codons, these library will be used to perform cellular assays (high-throughput screening assays for selection).This selection will be based on the loss of bacterial resistance to a given ²-lactam antibiotic from cells (colonies) where inhibition of the enzyme (²-lactamase) by a peptide clone occurs. 2) There will also be a search for new inhibitors from rational development usinf transition metal complexes. (AU)